Alios BioPharma

The company's business was centered on the discovery and development of novel antiviral drugs. Its core asset was a proprietary discovery platform, which combined a chemical library of nucleoside analogs with advanced, virology-based screening systems to identify promising therapeutic candidates. This model involved advancing these candidates through preclinical and clinical trials, with the ultimate goal of securing regulatory approval and commercialization. The company's primary clients would have been patients suffering from specific viral infections, with its business strategy culminating in a high-value exit via acquisition.

A significant achievement for Alios BioPharma was its acquisition by Johnson & Johnson for approximately $1.75 billion in cash, a deal completed in November 2014. Following this transaction, Alios was integrated into Janssen Pharmaceutical Companies, the pharmaceutical division of Johnson & Johnson, to bolster its infectious diseases pipeline. At the time of the acquisition, Alios's leading product candidate was AL-8176, an orally administered antiviral therapy in Phase 2 studies for treating respiratory syncytial virus (RSV) in infants. The portfolio also included promising early-stage compounds intended for the treatment of hepatitis C (HCV), which complemented Janssen's existing efforts in that area.